|
|||
Bench to Market: Idea Evaluation and Commercialization for Product-market FitJune 25, 2015, 6:00 PM to 8:30 PM (PDT) Berkeley, CaliforniaAbout the Event:Commercialization of today's nanoscale science and technology offers not only near-term solutions for many of today's serious problems, but it can also build infrastructure, markets, and support to further Foresight's long-term goal of developing advanced nanotechnology based upon productive nanosystems and high-throughput atomically precise manufacturing. With this interest in promoting a thriving entrepreneurial culture, Foresight was happy to co-sponsor this event from the Berkeley Postdoc Entrepreneur Program's (BPEP) “Ph.D. to Startup” Workshop Series: Bench to Market: Idea Evaluation and Commercialization for Product-market FitAn Event for Graduate Students, Postdocs and FacultyEvent details from Eventbrite:
The workshop began with the presentation by Dr. Kirn "Building a biotherapeutics company: lessons learned from a serial entrepreneur". Dr. Kirn began by asking "Why do Biotherapeutic Companies matter?" He supported his answer—that they provide the best way to translate research results into clinical benefits for patients— with his experiences developing oncolytic viruses at Onyx Pharmaceuticals and Jennerex Biotherapeutics, and most recently, gene therapeutic products at 4D Molecular Therapeutics, where he is Co-Founder, President & CEO; Co-Chairman. Most of Dr. Kirn's presentation focused on how to finance biotherapeutics startup companies. He noted that the average cost to get drugs to patients is $150 million invested over more than 10 years. Taking into account the fact that most biotherapeutic product development efforts fail, the cost averaged over the successful efforts is about $1 billion. Faced with the cost of raising so much capital, one might consider licensing the technology to a large pharmaceutical company. Dr. Kirn noted, however, that this is a quite risky option since big pharma companies turn over their portfolios every 3 to 5 years, often bringing in new staff and managers, so that your project would have to survive several such turnovers to make it to patients. The advantage of biotech companies is that they combine focus, agility, and speed. Describing the basic methods to raise capital, he also touched on some of the pitfalls of each: how to value the company, how to keep control of the board, how to delineate the rights of investors vs. the rights of the founders. From his experiences moving products from the benchtop to the market with three biotherapeutics companies, based on different technologies, founded at different times in different market environments with respect to current scientific fashions and current financial circumstances, and using different mixtures of methods to raise capital, Dr. Krin drew a number of lessons:
Library of Foresight Institute Conferences on Nanotechnology, 1989–2015 Library of Foresight Vision Weekends and Senior Associates Gatherings, 1992–2008
|
News & EventsForesight Programs
|
Home About Foresight Blog News & Events Roadmap About Nanotechnology Resources Facebook Contact Privacy Policy Foresight materials on the Web are ©1986–2024 Foresight Institute. All rights reserved. Legal Notices. |
Web site developed by Stephan Spencer and Netconcepts; maintained by James B. Lewis Enterprises. |